FAM171A1: A Potential Drug Target and Biomarker for Astroprincin

Target Name: FAM171A1

NCBI ID: G221061

FAM171A1

FAM171A1: A Potential Drug Target and Biomarker for Astroprincin

Abstract:

Astroprincin, a novel astrocytoma-associated protein, has been identified as a potential drug target and biomarker for various neurological disorders. Its unique structure and expression pattern in various tissues have piqued the interest of researchers, leading to a comprehensive study on its localization, function, and potential therapeutic applications. In this article, we will discuss the current understanding of Astroprincin, its potential implications as a drug target, and its potential as a biomarker for various neurological disorders.

Introduction:

Astrocytoma, also known as glioblastoma, is one of the most common malignant brain tumors, accounting for approximately 15% of all human malignancies. Despite advances in surgical and radiation treatments, the survival rate for glioblastoma remains high, with a five-year survival rate of approximately 70%. The devastating impact of glioblastoma on human life is due to its uncontrolled growth and the high recurrence rate after surgery and radiation therapy.

Recent studies have identified that astrocytoma tumors exhibit increased expression of various astrocytic markers, including GLT-1, a transcription factor that promotes astrocytic differentiation. GLT-1 is a key regulator of astrocytoma development and has been implicated in the development and progression of astrocytoma.

FAM171A1: A novel astrocytoma-associated protein

FAM171A1, a member of the family of transmembrane proteins known as the Kinesin-67 (K67) gene family, has been identified as a novel astrocytoma-associated protein. FAM171A1 is expressed in various tissues, including brain, spleen, and pancreas, and has been shown to localize to the endoplasmic reticulum (ER) and to be involved in the regulation of intracellular signaling pathways.

Structure and localization of FAM171A1

The FAM171A1 protein has a unique structure, consisting of a long N-terminus, a single transmembrane domain, and a C-terminus. The N-terminus of FAM171A1 contains a putative G protein-coupled receptor (GPCR) domain, which is involved in the regulation of intracellular signaling pathways. The single transmembrane domain of FAM171A1 contains a unique motif, known as the \"FAM171A1 signature,\" which is responsible for its unique localization to the ER and its regulation by various intracellular signaling pathways.

Function and potential therapeutic applications

FAM171A1 is involved in the regulation of various intracellular signaling pathways, including the TGF-β pathway. This pathway is involved in the development and maintenance of astrocytoma, and targeting FAM171A1 as a drug target may be a promising approach for the treatment of astrocytoma.

FAM171A1 has also been shown to play a role in the regulation of cell adhesion and migration. This suggests that targeting FAM171A1 may be a useful approach for the treatment of various neurological disorders, including cancer.

In addition to its potential therapeutic applications, FAM171A1 has also been identified as a potential biomarker for astrocytoma. The FAM171A1 protein is expressed in various tissues and has been shown to be involved in the regulation of intracellular signaling pathways, including the TGF-β pathway. This suggests that FAM171A1 may be a useful biomarker for the diagnosis and monitoring of astrocytoma.

Conclusion:

In conclusion, Astro

Protein Name: Family With Sequence Similarity 171 Member A1

Functions: Involved in the regulation of the cytoskeletal dynamics, plays a role in actin stress fiber formation

The "FAM171A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM171A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets